FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

vvasnington,	D.C. 20549	

Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Smith Hunter C					RF	2. Issuer Name and Ticker or Trading Symbol RHYTHM PHARMACEUTICALS, INC. [RYTM]									5. Relationship of Reporting (Check all applicable) Director X Officer (give title			10% Ov	wner
	YTHM PHA	irst) ARMACEUTIC FREET, 12TH F		2.		3. Date of Earliest Transaction (Month/Day/Year) 02/09/2023									below) Chief Fina:	ncial	below) Officer	
(Street) BOSTON (City)			02116 (Zip)		, 4. If	Amer	ndmer	nt, Date o	of Origina	l Filed	(Month/D	ay/Yea	ar)	Line) K Form	filed by One	e Repo	g (Check Ap orting Perso n One Repo	n
	`			n-Deriv	ative	Sec	curiti	ies Ac	auired.	Dis	posed o	of. or	Ben	eficial	y Owne				
1. Title of Security (Instr. 3)		2. Trans	ransaction		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa	3. 4. Transaction Code (Instr. 5		curities Acquired (A) osed Of (D) (Instr. 3, 4			5. Amou Securiti Benefic Owned	unt of es ially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(,	A) or D)	Price	Transac	Reported (In Transaction(s) (Instr. 3 and 4)			
Common	on Stock 02/		02/09	02/09/2023				М		4,063	4,063 A		(1)	59	,177		D		
Common	Common Stock 02/0		02/09	0/2023	2023			S ⁽²⁾		1,398	8	D	\$27.6	6 57,779			D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date, Transaction			on of Ex		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		4)	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership tt (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	N C	Amount or Number of Shares					
Restricted Stock	(1)	02/09/2023			M			4,063	(3)		(3)	Comr		4,063	\$0	12,187	7	D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- 2. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
- 3. The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date.

/s/ Hunter C. Smith

02/13/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.